AI Summary
✦ ClarthaValuation Metrics
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
12.53
Current
11.64
Overvalued
13.73
Undervalued
11.51
5Y Average
59.75
Current
55.48
Overvalued
65.43
Undervalued
54.88
5Y Average
3.34
Current
3.09
Overvalued
3.84
Undervalued
2.84
Peers & Comparison
Sector: Health Care · Theme: Biotechnology
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
BIOCON LIMITED. BIOCONBiotechnology | +10.0% | 2.9% | 120.9x Premium | +68% vs avg | +18.3% |
ANTHEM BIOSCIENCES LTD ANTHEMBiotechnology | -22.6% | 28.7% | 87.5x Premium | +21% vs avg | +6.5% |
SAI LIFE SCIENCES LIMITED SAILIFEBiotechnology | +11.7% | 16.1% | 85.4x Premium | +18% vs avg | +62.7% |
ACUTAAS CHEMICALS LIMITED ACUTAASBiotechnology | +59.1% | 26.4% | 92.0x Premium | +28% vs avg | +142.6% |
NEULAND LAB LTD. NEULANDLABPharmaceuticals | +119.2% | 2.3% | 60.9x Undervalued | -16% vs avg | +69.5% |
SUDEEP PHARMA LIMITED SUDEEPPHRMPharmaceuticals | +26.7% | 27.0% | 68.3x Fair | -5% vs avg | +42.6% |
STRIDES PHARMA SCI LTD STARPharmaceuticals | +13.0% | 12.3% | 14.8x Undervalued | -79% vs avg | +15.6% |
YATHARTH HOSP & TRA C S L YATHARTHHospitals & Diagnostic Centres | +54.0% | 13.2% | 46.9x Undervalued | -35% vs avg | +21.1% |
ONESOURCE SPECL PHARMA L is compared against the Biotechnology cohort. Peers include BIOCON LIMITED., ANTHEM BIOSCIENCES LTD, SAI LIFE SCIENCES LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹446 CrJun 2026Latest net profit
₹51 CrJun 2026Latest EPS
₹4.47Jun 2026Net margin
26.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 34 | 56 | 73 | 240 | 245 | 337 | 477 | 321 | 375 | 290 | 419 | 446 |
| Expenses + | 72 | 67 | 76 | 230 | 223 | 237 | 240 | 241 | 274 | 277 | 344 | 332 |
| Operating Profit | -38 | -10 | -3 | 10 | 22 | 99 | 237 | 80 | 102 | 13 | 75 | 114 |
| OPM % | -113% | -18% | -3.6% | 4.3% | 9% | 30% | 50% | 25% | 27% | 4.4% | 18% | 26% |
| Other Income + | -32 | -74 | 3 | -1 | -3 | -95 | 3 | 5 | 3 | -2 | 4 | 4 |
| Interest | 25 | 26 | 20 | 41 | 44 | 44 | 32 | 27 | 33 | 38 | 22 | 31 |
| Depreciation | 18 | 20 | 20 | 34 | 33 | 34 | 34 | 33 | 34 | 35 | 35 | 36 |
| Profit before tax | -113 | -130 | -40 | -65 | -58 | -73 | 174 | 25 | 37 | -62 | 21 | 51 |
| Tax % | 0% | 0% | 0% | -63% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit + | -113 | -130 | -40 | -24 | -58 | -73 | 174 | 25 | 37 | -62 | 21 | 51 |
| EPS in Rs | -6.38 | 15.22 | 2.17 | 3.24 | -5.43 | 1.87 | 4.47 | |||||
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation